Hong Kong stocks surged | Hengrui Medicine (01276.HK) rose more than 3% as the application for listing of Haiqupaba ethylamine tablets was accepted by the National Medical Products Administration.

According to the Zhitong Finance APP, Hengrui Medicine (01276.HK) rose more than 3%, as of the time of publication, it rose 3.19%, to 77.75 Hong Kong dollars, with a turnover of 1.46 billion Hong Kong dollars.